This document is an excerpt from the EUR-Lex website
Document 52021XC1229(07)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 November 2021 to 30 November 2021 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Súhrn rozhodnutí Európskej únie o povolení na uvedenie liekov na trh od 1. novembra 2021 do 30. novembra 2021 [Uverejnené v súlade s článkom 13 alebo 38 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]
Súhrn rozhodnutí Európskej únie o povolení na uvedenie liekov na trh od 1. novembra 2021 do 30. novembra 2021 [Uverejnené v súlade s článkom 13 alebo 38 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]
PUB/2021/1011
Ú. v. EÚ C 527, 29.12.2021, p. 1–12
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
29.12.2021 |
SK |
Úradný vestník Európskej únie |
C 527/1 |
Súhrn rozhodnutí Európskej únie o povolení na uvedenie liekov na trh od 1. novembra 2021 do 30. novembra 2021
[Uverejnené v súlade s článkom 13 alebo 38 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004 (1)]
(2021/C 527/01)
— Udelenie povolenia na uvedenie na trh [článok 13 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]: Prijaté
Dátum rozhodnutia |
Názov lieku |
INN (medzinárodný neregistrovaný názov) |
Držiteľ povolenia na uvedenie na trh |
Číslo záznamu v registri Spoločenstva |
Lieková forma |
Kód ATC (anatomicko-terapeuticko-chemický kód) |
Dátum oznámenia |
||
12.11.2021 |
Libmyris |
adalimumab |
|
EU/1/21/1590 |
Injekčný roztok |
L04AB04 |
16.11.2021 |
||
12.11.2021 |
Rivaroxaban Mylan |
rivaroxaban |
|
EU/1/21/1588 |
Tableta |
B01AF01 |
3.12.2021 |
||
15.11.2021 |
Hukyndra |
adalimumab |
|
EU/1/21/1589 |
Injekčný roztok |
L04AB04 |
16.11.2021 |
||
15.11.2021 |
Sugammadex Mylan |
sugamadex |
|
EU/1/21/1583 |
Injekčný roztok |
V03AB35 |
3.12.2021 |
||
15.11.2021 |
Vumerity |
diroximélium-fumarát |
|
EU/1/21/1585 |
Gastrorezistentná kapsula, tvrdá |
L04AX09 |
16.11.2021 |
||
18.11.2021 |
GAVRETO |
pralsetinib |
|
EU/1/21/1555 |
Tvrdá kapsula |
L01EX23 |
22.11.2021 |
||
18.11.2021 |
QINLOCK |
ripretinib |
|
EU/1/21/1569 |
Tableta |
L01EX19 |
24.11.2021 |
||
22.11.2021 |
Artesunate Amivas |
artesunát |
|
EU/1/21/1582 |
Prášok a rozpúšťadlo na injekčný roztok |
P01BE03 |
24.11.2021 |
||
22.11.2021 |
Brukinsa |
zanubrutinib |
|
EU/1/21/1576 |
Tvrdá kapsula |
L01EL03 |
23.11.2021 |
||
22.11.2021 |
Trodelvy |
sacituzumab govitekan |
|
EU/1/21/1592 |
Prášok na prípravu infúzneho koncentrátu |
L01FX17 |
23.11.2021 |
— Udelenie povolenia na uvedenie na trh [článok 13 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]: Zamietnuté
Dátum rozhodnutia |
Názov lieku |
Držiteľ povolenia na uvedenie na trh |
Číslo záznamu v registri Spoločenstva |
Dátum oznámenia |
||
15.11.2021 |
Raylumis |
|
— |
17.11.2021 |
— Zmena povolenia na uvedenie na trh [článok 13 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]: Prijaté
Dátum rozhodnutia |
Názov lieku |
Držiteľ povolenia na uvedenie na trh |
Číslo záznamu v registri Spoločenstva |
Dátum oznámenia |
||
3.11.2021 |
Besponsa |
|
EU/1/17/1200 |
4.11.2021 |
||
3.11.2021 |
Comirnaty |
|
EU/1/20/1528 |
3.11.2021 |
||
3.11.2021 |
Extavia |
|
EU/1/08/454 |
8.11.2021 |
||
3.11.2021 |
Fulvestrant Mylan |
|
EU/1/17/1253 |
4.11.2021 |
||
3.11.2021 |
Lamzede |
|
EU/1/17/1258 |
5.11.2021 |
||
3.11.2021 |
Pregabalin Mylan |
|
EU/1/15/997 |
4.11.2021 |
||
3.11.2021 |
Pregabalin Mylan Pharma |
|
EU/1/15/998 |
5.11.2021 |
||
3.11.2021 |
Spikevax |
|
EU/1/20/1507 |
4.11.2021 |
||
9.11.2021 |
Clopidogrel Viatris |
|
EU/1/09/568 |
30.11.2021 |
||
9.11.2021 |
Enyglid |
|
EU/1/09/580 |
1.12.2021 |
||
9.11.2021 |
Luxturna |
|
EU/1/18/1331 |
10.11.2021 |
||
9.11.2021 |
Sutent |
|
EU/1/06/347 |
10.11.2021 |
||
9.11.2021 |
Talmanco |
|
EU/1/16/1153 |
1.12.2021 |
||
9.11.2021 |
Tegsedi |
|
EU/1/18/1296 |
30.11.2021 |
||
9.11.2021 |
Vaxzevria |
|
EU/1/21/1529 |
10.11.2021 |
||
11.11.2021 |
Spikevax |
|
EU/1/20/1507 |
12.11.2021 |
||
12.11.2021 |
Akynzeo |
|
EU/1/15/1001 |
19.11.2021 |
||
12.11.2021 |
Atriance |
|
EU/1/07/403 |
15.11.2021 |
||
12.11.2021 |
Atripla |
|
EU/1/07/430 |
15.11.2021 |
||
12.11.2021 |
Daptomycin Hospira |
|
EU/1/17/1175 |
16.11.2021 |
||
12.11.2021 |
Dzuveo |
|
EU/1/18/1284 |
16.11.2021 |
||
12.11.2021 |
Edistride |
|
EU/1/15/1052 |
15.11.2021 |
||
12.11.2021 |
Enhertu |
|
EU/1/20/1508 |
2.12.2021 |
||
12.11.2021 |
Evoltra |
|
EU/1/06/334 |
16.11.2021 |
||
12.11.2021 |
Iasibon |
|
EU/1/10/659 |
16.11.2021 |
||
12.11.2021 |
Jyseleca |
|
EU/1/20/1480 |
15.11.2021 |
||
12.11.2021 |
Lacosamide Accord |
|
EU/1/17/1230 |
15.11.2021 |
||
12.11.2021 |
Lyrica |
|
EU/1/04/279 |
3.12.2021 |
||
12.11.2021 |
Ninlaro |
|
EU/1/16/1094 |
1.12.2021 |
||
12.11.2021 |
Nucala |
|
EU/1/15/1043 |
15.11.2021 |
||
12.11.2021 |
Olanzapín Mylan |
|
EU/1/08/475 |
15.11.2021 |
||
12.11.2021 |
Olumiant |
|
EU/1/16/1170 |
16.11.2021 |
||
12.11.2021 |
Sevelamer carbonate Winthrop |
|
EU/1/14/952 |
7.12.2021 |
||
12.11.2021 |
SomaKit TOC |
|
EU/1/16/1141 |
16.11.2021 |
||
12.11.2021 |
Steglujan |
|
EU/1/18/1266 |
15.11.2021 |
||
12.11.2021 |
Stelara |
|
EU/1/08/494 |
15.11.2021 |
||
12.11.2021 |
Suliqua |
|
EU/1/16/1157 |
15.11.2021 |
||
12.11.2021 |
Tadalafil Lilly |
|
EU/1/17/1177 |
15.11.2021 |
||
12.11.2021 |
Tivicay |
|
EU/1/13/892 |
17.11.2021 |
||
12.11.2021 |
Viagra |
|
EU/1/98/077 |
3.12.2021 |
||
12.11.2021 |
Xermelo |
|
EU/1/17/1224 |
8.12.2021 |
||
15.11.2021 |
Aldurazyme |
|
EU/1/03/253 |
7.12.2021 |
||
15.11.2021 |
Brilique |
|
EU/1/10/655 |
17.11.2021 |
||
15.11.2021 |
Clopidogrel Taw Pharma |
|
EU/1/09/559 |
25.11.2021 |
||
15.11.2021 |
Dovato |
|
EU/1/19/1370 |
17.11.2021 |
||
15.11.2021 |
Emtricitabine/Tenofovir disoproxil Mylan |
|
EU/1/16/1133 |
16.11.2021 |
||
15.11.2021 |
Fasturtec |
|
EU/1/00/170 |
16.11.2021 |
||
15.11.2021 |
Forxiga |
|
EU/1/12/795 |
17.11.2021 |
||
15.11.2021 |
Gardasil |
|
EU/1/06/357 |
17.11.2021 |
||
15.11.2021 |
Hizentra |
|
EU/1/11/687 |
18.11.2021 |
||
15.11.2021 |
Hulio |
|
EU/1/18/1319 |
17.11.2021 |
||
15.11.2021 |
Invokana |
|
EU/1/13/884 |
16.11.2021 |
||
15.11.2021 |
Jorveza |
|
EU/1/17/1254 |
16.11.2021 |
||
15.11.2021 |
Kevzara |
|
EU/1/17/1196 |
16.11.2021 |
||
15.11.2021 |
KEYTRUDA |
|
EU/1/15/1024 |
20.11.2021 |
||
15.11.2021 |
Myalepta |
|
EU/1/18/1276 |
18.11.2021 |
||
15.11.2021 |
Praluent |
|
EU/1/15/1031 |
16.11.2021 |
||
15.11.2021 |
Remicade |
|
EU/1/99/116 |
19.11.2021 |
||
15.11.2021 |
Rilutek |
|
EU/1/96/010 |
18.11.2021 |
||
15.11.2021 |
Sirturo |
|
EU/1/13/901 |
16.11.2021 |
||
15.11.2021 |
Skyrizi |
|
EU/1/19/1361 |
16.11.2021 |
||
15.11.2021 |
Thyrogen |
|
EU/1/99/122 |
17.11.2021 |
||
15.11.2021 |
Triumeq |
|
EU/1/14/940 |
17.11.2021 |
||
15.11.2021 |
Truxima |
|
EU/1/16/1167 |
16.11.2021 |
||
15.11.2021 |
Xeljanz |
|
EU/1/17/1178 |
17.11.2021 |
||
15.11.2021 |
Yellox |
|
EU/1/11/692 |
2.12.2021 |
||
15.11.2021 |
Zercepac |
|
EU/1/20/1456 |
16.11.2021 |
||
15.11.2021 |
Zercepac |
|
EU/1/20/1456 |
16.11.2021 |
||
15.11.2021 |
Zoledronic acid Mylan |
|
EU/1/12/786 |
16.11.2021 |
||
15.11.2021 |
Zonisamide Mylan |
|
EU/1/16/1093 |
16.11.2021 |
||
18.11.2021 |
Abecma |
|
EU/1/21/1539 |
21.11.2021 |
||
18.11.2021 |
Aripiprazole Mylan Pharma |
|
EU/1/15/1005 |
19.11.2021 |
||
18.11.2021 |
Axumin |
|
EU/1/17/1186 |
23.11.2021 |
||
18.11.2021 |
Aybintio |
|
EU/1/20/1454 |
22.11.2021 |
||
18.11.2021 |
Beovu |
|
EU/1/19/1417 |
26.11.2021 |
||
18.11.2021 |
Champix |
|
EU/1/06/360 |
19.11.2021 |
||
18.11.2021 |
Comirnaty |
|
EU/1/20/1528 |
18.11.2021 |
||
18.11.2021 |
Marixino |
|
EU/1/13/820 |
22.11.2021 |
||
18.11.2021 |
Ogivri |
|
EU/1/18/1341 |
22.11.2021 |
||
18.11.2021 |
Opatanol |
|
EU/1/02/217 |
19.11.2021 |
||
18.11.2021 |
Pemetrexed Krka |
|
EU/1/18/1283 |
22.11.2021 |
||
18.11.2021 |
Prometax |
|
EU/1/98/092 |
19.11.2021 |
||
18.11.2021 |
Ritonavir Mylan |
|
EU/1/17/1242 |
19.11.2021 |
||
18.11.2021 |
Steglujan |
|
EU/1/18/1266 |
20.11.2021 |
||
18.11.2021 |
Tecartus |
|
EU/1/20/1492 |
19.11.2021 |
||
18.11.2021 |
Xagrid |
|
EU/1/04/295 |
19.11.2021 |
||
18.11.2021 |
Xoterna Breezhaler |
|
EU/1/13/863 |
19.11.2021 |
||
18.11.2021 |
Zeffix |
|
EU/1/99/114 |
19.11.2021 |
||
18.11.2021 |
Zeposia |
|
EU/1/20/1442 |
21.11.2021 |
||
19.11.2021 |
Aripiprazole Mylan Pharma |
|
EU/1/15/1005 |
22.11.2021 |
||
22.11.2021 |
Briviact |
|
EU/1/15/1073 |
1.12.2021 |
||
22.11.2021 |
BYANNLI |
|
EU/1/20/1453 |
23.11.2021 |
||
22.11.2021 |
Foclivia |
|
EU/1/09/577 |
23.11.2021 |
||
22.11.2021 |
Lacosamide Accord |
|
EU/1/17/1230 |
23.11.2021 |
||
22.11.2021 |
Pregabalin Zentiva k.s |
|
EU/1/16/1166 |
23.11.2021 |
||
22.11.2021 |
Saxenda |
|
EU/1/15/992 |
23.11.2021 |
||
22.11.2021 |
Suliqua |
|
EU/1/16/1157 |
23.11.2021 |
||
22.11.2021 |
Talmanco |
|
EU/1/16/1153 |
23.11.2021 |
||
22.11.2021 |
TOBI Podhaler |
|
EU/1/10/652 |
23.11.2021 |
||
22.11.2021 |
Zypadhera |
|
EU/1/08/479 |
23.11.2021 |
||
23.11.2021 |
Vaxzevria |
|
EU/1/21/1529 |
23.11.2021 |
||
26.11.2021 |
Clopidogrel Teva |
|
EU/1/09/540 |
30.11.2021 |
||
26.11.2021 |
Comirnaty |
|
EU/1/20/1528 |
26.11.2021 |
||
26.11.2021 |
Corbilta |
|
EU/1/13/859 |
30.11.2021 |
||
26.11.2021 |
Kisplyx |
|
EU/1/16/1128 |
29.11.2021 |
||
26.11.2021 |
Lenvima |
|
EU/1/15/1002 |
29.11.2021 |
||
26.11.2021 |
Lyxumia |
|
EU/1/12/811 |
29.11.2021 |
||
26.11.2021 |
NeoRecormon |
|
EU/1/97/031 |
1.12.2021 |
||
26.11.2021 |
Pritor |
|
EU/1/98/089 |
30.11.2021 |
||
26.11.2021 |
Relvar Ellipta |
|
EU/1/13/886 |
29.11.2021 |
||
26.11.2021 |
Repatha |
|
EU/1/15/1016 |
29.11.2021 |
||
26.11.2021 |
Replagal |
|
EU/1/01/189 |
6.12.2021 |
||
26.11.2021 |
Rivaroxaban Accord |
|
EU/1/20/1488 |
24.10.2021 |
||
26.11.2021 |
Rivaroxaban Accord |
|
EU/1/20/1488 |
30.11.2021 |
||
26.11.2021 |
Uptravi |
|
EU/1/15/1083 |
29.12.2021 |
||
29.11.2021 |
Carmustine Obvius |
|
EU/1/18/1278 |
1.12.2021 |
||
29.11.2021 |
Hirobriz Breezhaler |
|
EU/1/09/594 |
30.11.2021 |
||
29.11.2021 |
IntronA |
|
EU/1/99/127 |
1.12.2021 |
||
29.11.2021 |
Simulect |
|
EU/1/98/084 |
30.11.2021 |
— Odňatie povolenia na uvedenie na trh [článok 13 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]
Dátum rozhodnutia |
Názov lieku |
Držiteľ povolenia na uvedenie na trh |
Číslo záznamu v registri Spoločenstva |
Dátum oznámenia |
||
3.11.2021 |
Pregabalin Mylan Pharma |
|
EU/1/15/998 |
5.11.2021 |
||
15.11.2021 |
Atripla |
|
EU/1/07/430 |
16.11.2021 |
||
18.11.2021 |
Skysona |
|
EU/1/21/1563 |
19.11.2021 |
||
30.11.2021 |
IntronA |
|
EU/1/99/127 |
1.12.2021 |
— Udelenie povolenia na uvedenie na trh [článok 38 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]: Prijaté
Dátum rozhodnutia |
Názov lieku |
INN (medzinárodný neregistrovaný názov) |
Držiteľ povolenia na uvedenie na trh |
Číslo záznamu v registri Spoločenstva |
Lieková forma |
Kód ATC (anatomicko-terapeuticko-chemický kód) |
Dátum oznámenia |
||
11.11.2021 |
Felpreva |
tigolaner/emodepsid/prazikvantel |
|
EU/2/21/277 |
Roztok na kvapkanie na kožu |
QP52AA51 |
12.11.2021 |
— Zmena povolenia na uvedenie na trh [článok 38 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]: Prijaté
Dátum rozhodnutia |
Názov lieku |
Držiteľ povolenia na uvedenie na trh |
Číslo záznamu v registri Spoločenstva |
Dátum oznámenia |
||
3.11.2021 |
Chanhold |
|
EU/2/19/236 |
5.11.2021 |
||
3.11.2021 |
Equilis Prequenza |
|
EU/2/05/056 |
5.11.2021 |
||
3.11.2021 |
Equilis Prequenza Te |
|
EU/2/05/057 |
5.11.2021 |
||
3.11.2021 |
Kexxtone |
|
EU/2/12/145 |
4.11.2021 |
||
11.11.2021 |
Cepedex |
|
EU/2/16/200 |
25.11.2021 |
||
11.11.2021 |
Coliprotec F4/F18 |
|
EU/2/16/202 |
15.11.2021 |
||
12.11.2021 |
Aivlosin |
|
EU/2/04/044 |
16.11.2021 |
||
12.11.2021 |
Simparica Trio |
|
EU/2/19/243 |
16.11.2021 |
||
26.11.2021 |
PREVEXXION RN |
|
EU/2/20/254 |
3.12.2021 |
||
29.11.2021 |
NexGard Combo |
|
EU/2/20/267 |
30.11.2021 |
— Odňatie povolenia na uvedenie na trh [článok 38 nariadenia Európskeho parlamentu a Rady (ES) č. 726/2004]
Dátum rozhodnutia |
Názov lieku |
Držiteľ povolenia na uvedenie na trh |
Číslo záznamu v registri Spoločenstva |
Dátum oznámenia |
||
15.11.2021 |
Coliprotec F4 |
|
EU/2/14/180 |
7.12.2021 |
Ak sa chcete oboznámiť s verejnou hodnotiacou správou o príslušných liekoch a s ňou súvisiacimi rozhodnutiami, môžete kontaktovať:
European Medicines Agency |
Domenico Scarlattilaan 6 |
1083 HS Amsterdam |
NETHERLANDS |